Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Auli Ropo"'
Publikováno v:
Clinical Ophthalmology (Auckland, N.Z.)
Lutz E Pillunat,1 Carl Erb,2 Auli Ropo,3 Friedemann Kimmich,4 Norbert Pfeiffer5 1Department of Ophthalmology, University Hospital Carl Gustav Carus, Dresden, 2Augenklinik am Wittenbergplatz, Berlin, Germany; 3Santen Europe, Helsinki, Finland; 4eyecon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::494a001b74af446caecaca9a53dc3b17
http://europepmc.org/articles/PMC5472425
http://europepmc.org/articles/PMC5472425
Autor:
Akihiro Iwata, Hisashi Kawata, Auli Ropo, Fenghe Lu, Makoto Aihara, Noriko Odani-Kawabata, Naveed K Shams
Publikováno v:
Japanese journal of ophthalmology. 64(4)
Omidenepag isopropyl (OMDI) is the prodrug of omidenepag, a selective, non-prostaglandin, prostanoid EP2 receptor agonist, which has been shown to lower intraocular pressure (IOP) in patients with glaucoma and ocular hypertension (OHT). This study ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51fd1e4bc08bd44908d4f6dfeb2178e7
https://pubmed.ncbi.nlm.nih.gov/32572719
https://pubmed.ncbi.nlm.nih.gov/32572719
Autor:
Katrin Lorenz, Auli Ropo, Rupert R A Bourne, Carlo Enrico Traverso, Jouni Vuorinen, Kai Kaarniranta
Publikováno v:
BMJ Open
ObjectivesBimatoprost–timolol (bimatoprost 0.03%–timolol 0.5% fixed-dose combination [FDC]) and tafluprost–timolol (tafluprost 0.0015%–timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies av
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edb3bf6ce7ab2e8d25ebbaf6b4c1aa4d
https://pubmed.ncbi.nlm.nih.gov/30944129
https://pubmed.ncbi.nlm.nih.gov/30944129
Autor:
Auli Ropo, Kai Kaarniranta
Publikováno v:
Clinical Investigation.
Key points When prescribing intraocular pressure (IOP)-lowering medication for glaucoma, physicians’ considerations of a patient’s age, preferences and prior experience using different types of eye drop containers could potentially improve adhere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f849191dfae4509fac34548ec3237cab
https://doi.org/10.4172/clinical-investigation.1000126
https://doi.org/10.4172/clinical-investigation.1000126
Publikováno v:
Advances in Therapy
A new preservative-free fixed-dose combination of 0.0015% tafluprost, a prostaglandin F2α analog, and 0.5% timolol (TAF/TIM; Santen Oy, Tampere, Finland), a beta-adrenergic antagonist has recently been developed. The intraocular pressure (IOP) reduc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a68358b6d511c11e4843f4e7d3fcf17
https://doi.org/10.1007/s12325-014-0151-7
https://doi.org/10.1007/s12325-014-0151-7
Publikováno v:
Clinical Ophthalmology (Auckland, N.Z.)
Article
Introduction: Glaucoma patients frequently exhibit ocular surface side effects during treatment with prostaglandin eye drops. The present work investigated whether glaucoma patients suffering from signs and symptoms of ocular surface dis
Introduction: Glaucoma patients frequently exhibit ocular surface side effects during treatment with prostaglandin eye drops. The present work investigated whether glaucoma patients suffering from signs and symptoms of ocular surface dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec7aea5955cf703d4d3caf794baa9604
https://pubmed.ncbi.nlm.nih.gov/27041987
https://pubmed.ncbi.nlm.nih.gov/27041987
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics. 26:273-276
The aims of this study were to investigate how elderly people handle single-use eye drop dispensers (unit-dose pipettes) and to compare the performance with conventional eye drop bottles.In this open-label study, the handling of unit-dose pipettes an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96cd9d50590405912a8a9c9f92848614
https://doi.org/10.1089/jop.2009.0111
https://doi.org/10.1089/jop.2009.0111
Publikováno v:
Acta Ophthalmologica. 88:12-19
Purpose: The objective of the study was to compare the long-term efficacy and safety of tafluprost 0.0015% with latanoprost 0.005% eye drops in patients with open-angle glaucoma or ocular hypertension. Methods: This double-masked, active-controlled,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72758b58c9f8a4e65c394d6237964464
https://doi.org/10.1111/j.1755-3768.2010.01862.x
https://doi.org/10.1111/j.1755-3768.2010.01862.x
Autor:
A Tolonen, Marjo Volotinen, Auli Ropo, E. Aine, J Mäenpää, H Kautiainen, Heikki Vapaatalo, J Uusitalo
Publikováno v:
European Journal of Pharmaceutical Sciences. 36:292-296
Purpose Ophthalmic timolol has been used for decades in the treatment of glaucoma and ocular hypertension, traditionally in aqueous 0.5% eye drops. Recently a timolol 0.1% hydrogel has been developed to improve systemic safety. The aim of the present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beb9834361542d4b9fe5fc9d930b35d9
https://doi.org/10.1016/j.ejps.2008.10.004
https://doi.org/10.1016/j.ejps.2008.10.004
Publikováno v:
Acta Ophthalmologica. 86:7-13
Purpose Prostanoid F(2alpha) (PF(2alpha)) analogues are commonly used as first-line treatment of glaucoma. Tafluprost is a newly synthesized PF(2alpha) derivative and represents the first PF(2alpha) analogue with a fully preservative-free formulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb1fb3da27ab59be1befcf1d13cf6de4
https://doi.org/10.1111/j.1755-3768.2008.01380.x
https://doi.org/10.1111/j.1755-3768.2008.01380.x